MCM. Janelle Cambron-Mellott

M. Janelle Cambron-Mellott

*This is an algorithmically generated author record based on publicly available information.

M. Janelle Cambron-Mellott has a total of 105 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Patient characteristics and clinical indicators influencing oncologists’ perceptions of prognosis in ovarian cancer: a discrete choice experiment

    by Robert L. Coleman, Zulikhat Segunmaru, Elizabeth A. Szamreta, Kathryn Krupsky, Kathleen Beusterien, M. Janelle Cambron-Mellott, Michael F. Barry, Nicole Kashine, Emily Mulvihill, Daniel Simmons

  • Open Access

    The Clinical, Humanistic, and Economic Burden of Idiopathic Hypersomnia in the United States: Analysis of the National Health and Wellness Survey

    by Caroleen Drachenberg, M. Janelle Cambron-Mellott, Lin Yang, Bridget L Balkaran, Marisa Whalen, David T Plante

    Purpose: Limited self-reported data on the real-world burden of idiopathic hypersomnia exist from a representative sample of the US general adult population. This study described the clinical, humanistic, and economic burden of adults with idiopathic hypersomnia compared to matched adults without idiopathic hypersomnia. Patients and Methods: This cross-sectional study used 2021 and 2023 US National Health and Wellness Survey data. Propensity score matching (1:2) was performed for adults (≥ 18 years) who self-reported a physician diagnosis of idiopathic hypersomnia and adults without idiopathic hypersomnia (non-idiopathic hypersomnia cohort). Post matching, outcomes were compared between cohorts using cluster-robust regression models; P values for primary outcomes were not adjusted for multiplicity. Results: Included were 163 adults with idiopathic hypersomnia (64.4% female, mean age 38.45 years) and 326 matched adults without idiopathic hypersomnia (66.0% female, mean age 39.60 years). The idiopathic hypersomnia cohort had higher prevalence of comorbidities (eg cardiovascular, cardiometabolic, sleep, psychiatric), higher mean Charlson comorbidity index scores (1.43 vs 0.34), and reported worse depression (PHQ-9) and anxiety (GAD-7) and poorer mental health, physical function (SF-36v2, RAND-36), and HRQoL (EQ-5D-5L, SF-6D, EQ-VAS) compared to the matched non-idiopathic hypersomnia cohort (P < 0.01). The idiopathic hypersomnia cohort reported more mean healthcare provider visits (13.34 vs 3.14), emergency department visits (0.88 vs 0.45), and hospitalizations (0.95 vs 0.35) in the past 6 months and higher annualized direct medical costs ($46,424.39 vs $14,700.21) than the matched non-idiopathic hypersomnia cohort (P < 0.05). The idiopathic hypersomnia cohort reported greater mean work productivity loss (49.07 vs 32.28) and activity impairment (48.22 vs 30.77), and annualized indirect costs ($15,269.22 vs $10,576.96) than the matched non-idiopathic hypersomnia cohort (P < 0.05). Conclusion: This study highlights the substantial real-world burden, including comorbidity, HRQoL, and economic, of idiopathic hypersomnia compared to the matched non-idiopathic hypersomnia cohort. Plain Language Summary: Idiopathic hypersomnia is a sleep disorder that causes extreme daytime sleepiness, even after a full night of sleep. In this large US survey study, adults with idiopathic hypersomnia were compared with similar adults who did not have the condition. The study found that people with idiopathic hypersomnia had more health problems, including higher levels of depression and anxiety, and reported lower overall physical and mental well‑being than people without the condition. People with idiopathic hypersomnia also described greater challenges in daily life, such as reduced energy, difficulty staying alert, and trouble completing everyday activities. In addition, people with idiopathic hypersomnia used more healthcare services, had higher medical costs, and experienced greater work productivity loss than those without idiopathic hypersomnia. These findings suggest that idiopathic hypersomnia impacts many aspects of life, including health, work, finances, and day‑to‑day functioning, and they highlight the need for better support and treatment options for those living with this condition.

  • Open Access

    Lack of Knowledge and Understanding of Undetectable Equals Untransmittable (U = U) Among People Living with HIV in the United States: Results from a Cross-Sectional Survey

    by Bekana K Tadese, M Janelle Cambron-Mellott, Jean Marie Arduino, Bridget L Balkaran, Shakiba Eslamimehr, José M Zuniga

    Background: Launched in the United States (US) in 2016, the ‘undetectable equals untransmittable’ (U = U) message has revolutionized human immunodeficiency virus (HIV) management by affirming that individuals on antiretroviral therapy (ART) with undetectable viral loads (VL) cannot sexually transmit the virus. This study aimed to assess the knowledge and understanding of U = U and factors associated with the lack of understanding among people living with HIV (PLHIV) in the US. Methods: A cross-sectional, online survey was fielded from February to June 2022 in the US to PLHIV aged ≥18 years who were currently taking ART. Data on sociodemographic variables, HIV-related and general health characteristics were collected. The study assessed the knowledge and understanding of U = U and sources of U = U information. Multivariable analyses were used to identify the factors associated with the lack of U = U understanding among PLHIV. Results: A total of 781 PLHIV completed the study and were included in the analysis. Most participants were P = 0.006), recent HIV diagnosis (6 months to P = 0.018), suboptimal ART adherence (OR: 2.74, 95% CI: 1.88-4.01, P < 0.001), and lack HCP communication about the importance of an undetectable VL compared to those who understood U = U. Conclusion: The study highlights substantial gaps in understanding U = U among PLHIV and in HCP-patient communication. These findings underscore the need for targeted education for both PLHIV and HCPs, emphasizing the clinical implications and benefits of U = U in relation to HIV prevention.


  • Open Access

    Moving Beyond Viral Suppression: Poor Patient–Provider Communication and Its Impact on Healthcare Outcomes Among People Living With HIV in the United States

    by Bekana K. Tadese, M. Janelle Cambron-Mellott, Jean Marie Arduino, Bridget L. Balkaran, Shakiba Eslamimehr, José M. Zuniga

    Background: While advancement in treatment have turned HIV into a manageable chronic condition achieving viral suppression, it has become imperative to focus on overall health and improving health-related quality of life of people living with HIV (PLHIV) beyond viral suppression. This study aimed to describe how PLHIV perceive and manage their overall health, factors influencing patient–provider communication, and the impact of poor patient–provider communication on health outcomes. Methods: This cross-sectional, online survey recruited HIV-positive adults in the United States between February 22 and June 2, 2022, via the Profiles Panel. Data on sociodemographic and health characteristics, and social determinants of health were collected. The study assessed how PLHIV view and manage their overall health by measuring self-rated overall health, Patient Activation Measure ® (PAM ® ), general and HIV-specific health locus of control (HLOC). Multivariable analyses were used to identify the barriers and unmet needs in the patient–primary HIV clinician communication. Results: Of the 781 PLHIV who completed the study, most participants were cisgender male (56.2%), non-Hispanic, White (51.5%), and <50 years old (67.0%). Over 90% of participants reported being virally suppressed or having an undetectable viral load. About one-third (31.5%) reported their overall health as either poor or fair. Participants were highly activated in managing their health with 58.0% at PAM level 3 and 33.3% at level 4 and had high scores across the dimensions of both general and HIV-specific HLOC. Overall, 18.2% of the participants reported suboptimal satisfaction and 16.8% reported facing difficulty in verbalizing their HIV-related health concerns with their primary HIV clinician. One-fourth of the participants reported “sometimes” or “never/rarely” discussing their HIV treatment medications with their primary HIV clinician. Furthermore, participants dissatisfied with their primary HIV clinician were twice as likely to self-report poor overall health (OR: 2.2, 95% CI: 1.38, 3.48). Conclusion: This study underscores the critical role of managing overall health by optimizing patient–provider relationships in influencing individual holistic well-being beyond viral suppression. Healthcare interventions should prioritize strategies to enhance patient communication and satisfaction, recognizing its profound impact on HIV and overall health outcomes.


  • Open Access

    Association between anhedonia severity and clinical, humanistic, and economic outcomes among US adults with major depressive disorder

    by Hrishikesh Kale, M Janelle Cambron-Mellott, Tiina Drissen, Kacper Perkowski, Kristen King-Concialdi, Manish K Jha

    Background: Anhedonia is a key symptom and part of the diagnostic criterion of major depressive disorder (MDD). However, the relationship between anhedonia severity and the clinical, humanistic, and economic burden among patients with MDD is poorly understood. Methods: Adults diagnosed with depression were identified from the 2022 US National Health and Wellness Survey (NHWS). Participants with depression were recontacted to participate in an online cross-sectional survey to collect data on anhedonia, using the Snaith-Hamilton Pleasure Scale (SHAPS). Multivariable analyses assessed the association of SHAPS score with health-related outcomes, while controlling for age, sex, race, comorbidity burden, and insurance status. The SHAPS (score range: 14 to 56) assesses the ability to experience pleasure, with higher scores indicating greater levels of anhedonia. Results: Of the 8270 NHWS respondents with depression who met inclusion criteria, 665 completed the recontact survey (mean age, 58.4 years; female, 78.3%). Mean SHAPS score was 25.4 (range, 14–47). After adjustments for covariates, higher SHAPS scores were significantly (all P <.05) associated with higher levels of depression (β = 0.211) and anxiety (β = 0.126), poorer mental (β = −0.339) and physical health-related quality of life (β = −0.178), greater impairment while working [rate ratio (RR) = 1.02], and higher direct medical costs (RR = 1.02). Conclusions: In adults with depression, higher levels of anhedonia were associated with greater clinical, humanistic, and economic burden. These results highlight the need for targeted treatments to help patients with MDD with prominent anhedonia attain improved clinical, humanistic, and work productivity outcomes.


  • Open Access

    Oncologist perceptions of “cure” and long-term management in advanced ovarian cancer in the United States: results from a cross-sectional survey

    by Robert L. Coleman, Zulikhat Segunmaru, Elizabeth A. Szamreta, Kathryn Krupsky, Kathleen Beusterien, M. Janelle Cambron-Mellott, Michael F. Barry, Nicole Kashine, Emily Mulvihill, Daniel Simmons


  • Open Access

    Physician preferences of biomarker testing strategies in newly diagnosed stage IV non-small cell lung cancer patients

    by Anne Shah, Jon Apple, Gabriela Burgos, Josh Lankin, Jesse Cohn, Emily Mulvihill, M. Janelle Cambron-Mellott

    Aim: To understand physicians' attitudes and behaviors regarding EGFR testing and retesting strategies in newly diagnosed metastatic non-small cell lung cancer patients.Materials & methods: Oncologists and pathologists completed an online, cross-sectional survey.Results: Most oncologists (73.3%) and pathologists (53.4%) agreed that concurrent testing increases sensitivity for detecting EGFR mutations. Upon tissue insufficiency, oncologists and pathologists reported using liquid biopsy 77.0% and 39.0% of the time, respectively. Tumor accessibility, smoking status, patient willingness and age were key drivers of tissue re-biopsy. Most oncologists reported high confidence in proceeding to first-line therapy based solely on liquid biopsy (60.7-80.0%); fewer pathologists (37.9%) were comfortable with this decision.Conclusion: Variation in physicians' perceptions of testing and retesting highlights the need for greater stakeholder consensus.


  • Open Access

    Burden of Wilson Disease among patients and care partners in the United States: results from a cross-sectional survey

    by Jon Vlasnik, M. Janelle Cambron-Mellott, Halley Costantino, Mary Kunjappu

    Objective: This study assessed the burden of Wilson Disease (WD) among patients and care partners (WD-CPs) in the US and compared it to a US general population of adults (GPs) and care partners (GP-CPs).Methods: This cross-sectional, self-reported survey included patients with WD and WD-CPs aged ≥18 years recruited through the Wilson Disease Association (WDA), while data for GPs and GP-CPs were obtained from the 2022 National Health and Wellness Survey. GPs and GP-CPs were propensity score matched (3:1) with WD patients and WD-CPs for demographics and health characteristics. Bivariate analysis evaluated differences in comorbidity burden and health-related outcomes of the WD cohorts compared to matched GP cohorts.Results: Thirty-seven patients with WD and 53 WD-CPs completed the survey. Most patients reported some treatment burden (73.3%), experienced sleep problems (60%), and visited a healthcare provider (HCP) in the past 6 months (91.9%). Compared with matched GPs, patients with WD had a significantly higher mortality risk (p < .001) and reported greater rates of chronic liver disease, cirrhosis (both, p < .001), migraines (p = .032), non-alcoholic steatohepatitis (p = .004), sleep problems (p = .009) and HCP visits (p = .002). Most WD-CPs (75.5%) reported high burden of caring (mean ZBI-12 score, 26.5) and more negative impact on esteem than GP-CPs.Conclusion: This study highlights the burden of WD experienced by patients and WD-CPs, with patients experiencing high treatment burden, comorbidity burden and healthcare resource utilization, and WD-CPs experiencing high impact of caring, including impact on employment and self-esteem.


  • Open Access

    The clinical, economic, and patient‐centric burden of insomnia symptom severity in adults with major depressive disorder in the United States

    by Kruti Joshi, M. Janelle Cambron‐Mellott, Halley Costantino, Alanna Pfau, Manish K. Jha

    Introduction: Insomnia is prevalent in adults with major depressive disorder (MDD) and is a key diagnostic criterion of MDD; however, little is understood about the burden of insomnia symptom severity in MDD. We evaluated the relationship between insomnia symptom severity and the clinical, economic, and patient‐centric burden among community‐dwelling individuals with MDD.Methods: Respondents with diagnosed depression who reported insomnia symptoms in the past 12 months (N = 4402) were identified from the 2019 United States National Health and Wellness Survey. Multivariable analyses assessed the association of Insomnia Severity Index (ISI) with health‐related outcomes while controlling for sociodemographic and health characteristics. Further analyses also controlled for depression severity (9‐item Patient Health Questionnaire).Results: Mean ISI score was 14.3 ± 5.6. Higher ISI was associated with greater depression severity (r = .51, p < .001). After adjustments, a one‐standard deviation (5.6‐point) increase in ISI score was significantly associated with higher depression (rate ratio [RR] = 1.36), anxiety (RR = 1.33) and daytime sleepiness (RR = 1.16) levels, more healthcare provider (RR = 1.13) and emergency room visits (RR = 1.31), hospitalizations (RR = 1.21), work productivity and activity impairment (RRs = 1.27 and 1.23, respectively), and poorer mental and physical health‐related quality of life (β = −3.853 and −1.999, respectively) (p < .001). These findings remained statistically significant when controlling for concurrent depression severity.Conclusion: In adults with MDD, greater insomnia symptom severity is associated with worse health‐related outcomes, which suggests the importance of addressing insomnia symptoms as a clinical target for treating MDD.


  • Open Access

    Factors associated with patient activation among individuals with depression within racial/ethnic groups in the United States

    by M. Janelle Cambron-Mellott, Nate Way, Jacqueline Pesa, Muideen Adigun, H. Jean Wright Ii